COMMUNIQUÉS West-GlobeNewswire

SafeSpace Global to Attend NIC Spring Conference to Engage Senior Living and Healthcare Leaders
27/03/2026
Knoxville, TN., March 27, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corp. (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions, dedicated to safety innovation [...]
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
27/03/2026
Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle [...]
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
27/03/2026
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 RUTHERFORD, N.J., March 27, 2026 (GLOBE [...]
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
27/03/2026
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and [...]
Communiqué de presse : La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple
27/03/2026
La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple Recommandation fondée sur des [...]
Lighthouse Autism Center Opening New Autism Therapy Center in Asheboro, North Carolina
27/03/2026
ASHEBORO, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Lighthouse Autism Center (LAC), a leading provider of center-based autism therapy, is proud to announce the opening of a new autism therapy center in Asheboro, North [...]
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
27/03/2026
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3K α pan-mutant inhibitors for breast cancer and vascular [...]
Axe Compute to Host Annual Report Conference Call
27/03/2026
Axe Compute to Report Fiscal Year 2025 Financial Results and File Annual Report on Form 10-K Conference call and webcast scheduled for April 1, 2026 PITTSBURGH, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Axe Compute ( [...]
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
27/03/2026
Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio [...]
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
27/03/2026
Company continues to evaluate strategic options to maximize shareholder value WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative [...]
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
27/03/2026
Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with [...]
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
27/03/2026
Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- [...]
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
27/03/2026
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
27/03/2026
Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not [...]
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
27/03/2026
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
27/03/2026
Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ( “ Clearmind ” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
27/03/2026
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs , Inc. (Nasdaq: AIDX), an early market [...]
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
27/03/2026
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the [...]
OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards
27/03/2026
Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the [...]

Pages